At a glance
- Originator MediQuest Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 08 Mar 2002 Oridigm Corporation is now called MediQuest Therapeutics
- 14 Apr 2000 Preclinical development for Cancer in USA (Unknown route)